After ‘tremendous’ FY 2021, Prescient Therapeutics well-funded to advance cancer-fighting therapies
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by...
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...
In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100,...
Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an...
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its...
Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results...
The US Food and Drug Administration has assigned a fast track designation to a new...
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.